Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: Findings using real-world claims data

Oncologist

Volumn 18, Issue 1, 2013, Pages 37-45

  Teitelbaum, April ^a   Ba Mancini, Abbie ^b   Huang, Hui ^b   Henk, Henry J ^a  

^a OPTUM   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Antineoplastic agents; Cost analysis; Cost of illness; Medicare; Multiple myeloma

Indexed keywords

ALPHA2B INTERFERON; BORTEZOMIB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AMBULATORY CARE; ARTICLE; COMORBIDITY; DRUG COST; ECONOMIC ASPECT; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES; THALIDOMIDE;

EID: 84873042632     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0113     Document Type: Article

References (49)

1. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2008. Available at http: //seer. cancer. gov/csr/1975_2008/. Accessed October 20, 2012.
2. Siegel R, Ward E, Brawley O et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
3. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: A comprehensive review. Clin Lymphoma Myeloma 2009; 9: 278-288.
4. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
5. Cavo M, Rajkumar SV, Palumbo A et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063-6073.
6. Palumbo A, Sezer O, Kyle R et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23: 1716-1730.
7. Bertolotti P, Bilotti E, Colson K et al. Management of side effects of novel therapies for multiple myeloma: Consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board. Clin J Oncol Nurs 2008; 12: 9-12.
8. Snowden JA, Ahmedzai SH, Ashcroft J et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011; 154: 76-103.
9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma (V1. 2012). Available at http: //www. nccn. org/professionals/physician_gls/ pdf/myeloma. pdf. Accessed October 20, 2012.
10. Harousseau JL, Dreyling M. Multiplemyeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v155-v157.
11. Brenner H, Gondos A Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
12. Brenner H, Gondos A Pulte D. Expected longterm survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009; 94: 270-275.
13. Kastritis E, Zervas K, Symeonidis A et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152-1157.
14. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiplemyelomaandthe impact of novel therapies. Blood 2008; 111: 2516-2520.
15. Fayers PM, Palumbo A, Hulin C et al. Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011; 118: 1239-1247.
16. Palumbo A, Bringhen S, Rossi D et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J Clin Oncol 2010; 28: 5101-5109.
17. Palumbo A, Adam Z, Kropff M et al. A phase 3 study evaluating the efficacy and safety of lenalidomide (len) combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients (pts) 65years (yrs) with newly diagnosed multiple myeloma (NDMM): Updated results for pts aged 65-75 yrs enrolled in MM-015. Blood 2011; 118: 220-221.
18. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
19. Cavo M, Tacchetti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 2010; 376: 2075-2085.
20. Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621-4629.
21. Rosinol L, Cibeira MT, Mateos MV et al. A phase IIIPETHEMA/GEMstudy of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/ thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib. Blood 2010; 116: 139a-140a.
22. Sonneveld P, Schmidt-Wolf I, van der Holt B et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood 2010; 116: 23a-24a.
23. Dimopoulos MA, Chen C, Spencer A et al. Longterm follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plusdexamethasonein patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23: 2147-2152.
24. Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 2007; 110: 3557-3560.
25. Blank PR, Levin R, Pestalozzi BC et al. Cost differences among treatment options for patients with refractory myeloma previously treated with high-dose chemotherapy and autologous stem-cell transplantation: Ananalysis from the U. S. and Swiss perspectives. J Clin Oncol 2011; 29: e16569.
26. Durie BG, Borrello I, Binder G et al. Treatment cost comparison in relapsed multiple myeloma. Haematologica 2011; 96: S140.
27. Fullerton DS, Huleatt H, Marantz JL et al. Treatment of relapsed myeloma: A budget impact model comparing single agent bortezomib with combination lenalidomide and high-dose dexamethasone. J Manag Care Pharmacy 2007; 13: 706-707.
28. Fullerton DSP, Trautman H, Huang H et al. A budget impact model comparing resource utilization of four approved therapies for multiple myeloma (MM) in the US. Blood 2007; 110: 3324.
29. Moller J, Nicklasson L Murthy A. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: Lenalidomide plus dexamethasone vs bortezomib. J Med Econ 2011; 14: 690-697.
30. Schey S, Stern S, Dhanasiri S et al. Cost-effectiveness of lenalidomide in multiple myeloma patients with 1 prior therapy in England and Wales. Blood 2011; 118: 1789.
31. Messori A, Maratea D, Nozzoli C et al. The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: An overview of clinical and economic information. Pharmacoeconomics 2011; 29: 269-285.
32. Armoiry X, Fagnani F, Benboubker L et al. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: A multi-centre retrospective cohort study. J Clin Pharm Ther 2011; 36: 19-26.
33. Hornberger J, Rickert J, Dhawan R et al. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. Eur J Haematol 2010; 85: 484-491.
34. Koleva D, Cortelazzo S, Toldo C et al. Healthcare costs of multiple myeloma: An Italian study. Eur J Cancer Care (Engl) 2011; 20: 330-336.
35. Schey S, Higginson I. Cost-effectiveness of lenalidomide in multiple myeloma. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 229-238.
36. Wang S-T, Huang H, Shi H et al. The cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States. Blood 2009; 114: 561-562.
37. Wang S-T, Huang H, Ba-Mancini A et al. The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma In the United States. Blood 2010; 116: 1060-1061.
38. Amonkar MM, Chastek B, Samant N et al. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population. J Med Econ 2011; 14: 421-432.
39. Baser O, Wei W, Henk HJ et al. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry. Curr Med Res Opin 2012; 28: 419-428.
40. Darkow T, Henk HJ, Thomas SK et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25: 481-496.
41. Lash S, Teitelbaum A, Henk HJ et al. Costs associated with second-line therapies for lung cancer. Am J Pharmacy Benefits 2011; 3: 21-29.
42. Cameron AC, Trivedi PK. Regression analysis of count data. Econometric Society Monograph No. 30. New York: Cambridge University Press, 1998.
43. Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005; 6: 93-109.
44. Ludwig H, Beksac M, Blade J et al. Multiple myeloma treatment strategies with novel agents in 2011: A European perspective. The Oncologist 2011; 16: 388-403.
45. Palumbo A, Attal M, Roussel M. Shifts inthetherapeutic paradigm for patients newly diagnosed with multiple myeloma: Maintenance therapy and overall survival. Clin Cancer Res 2011; 17: 1253-1263.
46. van de Donk NW, Lokhorst HM, Dimopoulos M et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011; 37: 266-283.
47. Richardson PG, Delforge M, Beksac M et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012; 26: 595-608.
48. Zamagni E, Brioli A, Tacchetti P et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 2011; 37: 209-219.
49. Dimopoulos MA, Terpos E, Chanan-Khan A et al. Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984.